Velan Inc. VLN

MONTREAL, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Velan Inc. (TSX: VLN) announced today that, on Wednesday, October 7, 2026, it will release its financial results for the second quarter ended August 31, 2026. The company will hold an analyst call on Thursday, October 8, 2026, at 8:00 a.m. (EDT) to discuss the results. To instantly join the conference call by phone, please use the following link to easily register close to the call start time. After registering, the system will call you instantly and

Velan Inc. (the "Corporation") (TSX: VLN) announced today that each director nominee listed in the Management Proxy Circular dated July 9, 2026, was elected as Director of the Corporation during the annual meeting of the shareholders of the Corporation held on August 25, 2026, in Montréal, Québec.

Despite a decline in sales and profits, Velan Inc (VLNSF) strengthens its financial position with a new credit facility and strategic acquisitions.

Velan (TSE:VLN) reported lower first-quarter sales, bookings and profitability as management said geopolitical and regional conflicts weighed on customer activity, order timing and shipment schedules, while the industrial valve maker pointed to a solid backlog and new financing as it begins a new ph

MONTREAL, July 09, 2026 (GLOBE NEWSWIRE) -- Velan Inc. (TSX: VLN) (“Velan” or the “Company”), a world-leading manufacturer of industrial valves, announced today financial results for its first quarter ended May 31, 2026. All amounts are expressed in U.S. dollars unless indicated otherwise. FIRST-QUARTER HIGHLIGHTS FROM CONTINUING OPERATIONS IFRS MEASURES Sales of $57.8 million, compared to $72.2 million last year, reflecting the geopolitical and regional conflicts which resulted in shipments bei

Velan Inc. (TSX: VLN) ("Velan" or the "Company") today announced the closing of the sale by its controlling shareholder, Velan Holding Co. Ltd. ("Velan Holding"), of its controlling interest in the Company to funds managed by Birch Hill Equity Partners Management Inc. ("Birch Hill"), together with planned board and management changes marking the next phase of Velan's strategic growth.

Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.

Velan (TSE:VLN) reported modest sales growth and a larger year-end backlog for fiscal 2026, while management pointed to tariffs, geopolitical tensions and shifting customer delivery schedules as factors weighing on profitability and order timing. On the company’s fourth-quarter earnings call, Chair

Despite a challenging environment, Velan Inc (VLNSF) reports improved sales and strategic advancements, positioning itself for future growth.

Velan Inc (VLNSF) reports robust order backlog growth and strategic advancements despite a slight decline in quarterly sales.

Velan (VLN.TO) overnight Wednesday said it swung to a third-quarter net income, although sales fell